Abstract-
I. INTRODUCTION
Despite their improving success rates, current modalities of cancer treatment including surgery, radiotherapy and chemotherapy are limited by their lack of efficacy in many cancers and by collateral disruption of non target physiological functions, tissues and organs. To overcome these limitations, current research is directed towards i) expanding the application of minimally invasive surgical procedures and ii) developing novel medical devices for precise delivery and uptake of therapeutic agents in target tissues. Therapeutic "electroporation" involves application of electric fields to target cells/tissues, thereby rendering their cell membranes transiently porous, thus making feasible the cellular uptake and efficacy of previously impermeant and ineffective therapeutic agents. Specifically the membrane permeability and cytotoxicity of the normally impermeant chemotherapeutic drug bleomycin can be dramatically enhanced by electroporation, thus achieving greater antitumor efficacy with reduced systemic drug concentrations and without the associated collateral injury. In clinical trials, this treatment has proved promising in a variety of tumour types, such as malignant melanoma, head and neck cancers and locally recurrent breast cancers (1, 2). Presently, electroporation based therapies are limited to the treatment of externally accessible tumours or tissues due to a reliance on macro electrodes such as calipers and needles (2, 3) . In this study we describe advances made in the development of novel flexible electrode arrays which may be modified for the application of electrochemotherapy or electrogenetherapy to a diversity of previously inaccessible tumours. We have designed, fabricated and evaluated novel flexible electrode arrays for incorporation into microsystem devices. We present results showing the efficacy of these flexible electrodes in-vitro and in-vivo suggesting that they may be used in conjunction with existing endoscopic based systems. Future application of these electrodes in humans might include the treatment of foregut cancers which are recalcitrant to conventional therapies and have a poor prognosis with a current five year survival rate of less than 10% (4).
II. METHODOLOGY Fabrication:
Gold electrodes were fabricated on flexible polyimide of 50µm thickness. Biocompatible grade Kapton TM was chosen ( Figure 2 ). The polymer was roughened using Argon plasma etching. This provided an excellent surface for the adhesion of chromium (20 nm) and gold (200 nm) layers that were evaporated through patterned stainless steel stencils (AlfaFry Technologies, Ireland) using a Temescal BJD1800I Tumour cell lines were grown in culture at 37°C in a humidified atmosphere of 5% CO 2 , in either Dulbecco's Modified Essential Medium (DMEM) or RPMI (Roswell Park Memorial Institute), supplemented with 10% ironsupplemented donor calf serum, 50 µg/ml gentamycin, 300 µg/ml L-glutamine, and 10 mM HEPES, pH 7.4. Tumour cells in tissue culture flasks were dislodged from the surface of the flasks by first removing the tissue culture media and washing the cells with an equal volume of phosphate buffered saline (PBS), cells were then treated with 0.05% Trypsin + 0.02% EDTA in PBS and incubated for about 2 min until cells became rounded and easy to dislodge from the flask surface. Tissue culture media was added to the harvested cells, and the cell suspensions were centrifuged at 180=g for 5 min. The cell pellets were then resuspended in the supplied medium, and the cell densities of the resulting cell suspensions were determined using a hemocytometer. All cell densities were determined at this point by visual count using a hemocytometer, viable cell counts were conducted by using the tryphan blue exclusion assay.
Cell Viability Assay:
Freshly pelleted tumour cells were resuspended in tissue culture medium and viable cell counts conducted using a hemocytometer. Cell concentrations of 1 x 10 5 in 100µl were prepared in tissue culture medium. Cells in a total volume of 100µl were pipetted onto the flexible electrode surface and an electroporation pulse delivered. After 10 minutes cells were diluted in 900µl of tissue culture medium. Six 100µl aliquots were pipetted into six wells of a 96 well plate, along with control (no cells) samples for medium-associated background fluorescence measurement, and incubated at 37°C at 5% CO 2 . Cultures were harvested by inverting the plates onto paper towels with gentle blotting to remove growth medium without disrupting adherent cells. After harvest, each plate was kept at -70°C until the assay was completed. Plates were thawed at room temperature, and 200 µl of the CYQUANT™ GR dye / lysis buffer (Molecular Probes, Netherlands) was added to each sample well. The samples were incubated in darkness for 2 to 5 min. Sample fluorescence was measured as above, and growth curves were plotted as fluorescence versus time.
Tumour induction and monitoring:
We used athymic nude mice for induction of human tumour xenografts and BalbC or C3H/Hen for isogeneic tumour models. Tumours were induced by injecting 2 × 10 6 tumour cells in 100µl of phosphate buffered saline (PBS) subcutaneously into the flank of female mice. When the tumours reached approximately 100 mm 3 in volume, mice were randomly divided into experimental groups and subjected to specific experimental protocols (n=6). Tumours were measured every 48 hours using a digital calliper. Tumour volume, v, was calculated using the standard formula v = ab 2 π/6, where a is the longest diameter and b is the next longest diameter perpendicular to a. All mice were humanely euthanized when the tumour volume reached 2 cm 3 .
Electrochemotherapy Protocol:
Mice were anaesthetised during all procedures using a mixture of halothane and O 2 . For the ECT, 0.25U bleomycin (Blenoxane, Sigma Chemical Co.) in 100µl PBS was injected intratumourally. The tumour was grasped percutaneously at the opposite margins of the tumour using two parallel flexible electrodes (6mm diameter) and their distance apart measured using a digital callipers. Good contact between the electrodes and the skin was assured by means of ultrasound gel (Rich Mar, USA). Electric pulses were generated by an electropulsator ECM 2001 (BTX Inc., San Diego, CA, USA) and incorporated four electric pulses (100µs, 1300 v/cm, 1Hz). In the electrochemotherapy protocol, mice were treated with electric pulses immediately after bleomycin injection. All treatments were well tolerated by the animals.
III. RESULTS
Finite element modeling using FEMLAB™ software was used to simulate the electric fields generated by the flexible electrodes as each of a range of pulse waveforms were applied. The electroporation parameters required optimization prior to experimental use. The variables
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analysed included the applied voltage, pulse shape, pulse duration, frequency, the total number of pulses applied and the pulse type (i.e., monopolar versus bipolar). This optimization minimised the number of electrode array design options produced as only those most likely to yield successful results were fabricated (Figure 1) . Initially the efficacy of the electrodes were assessed in-vitro by electroporation enhancement of the chemotherapeutic agent bleomycin. The effect of increasing the electrical field and bleomycin concentrations on a human prostate cell line are shown below. Cell viability was assessed 24 hours relative to control studies ( Figure 2 ). Lower voltages are ineffective irrespective of bleomycin concentration suggesting requirement of electroporation for optimal drug efficacy. Similar results were obtained from experiments conducted on oesophageal, renal, colon, fibrosarcoma, and breast cell lines. Additional experiments were performed to optimise the electric pulses delivered in terms of pulse length and frequency. We found four pulses at 1400v/cm with greater than 1µg of bleomycin to effectively kill nearly 90% of tumour cells. Additionally, the in-situ cell detection kit (Roche, MA, USA) was used to assess apoptosis in cells after electrochemotherapy. In all cases greater than 90% of the treated cells were apoptotic within six hours of the electrochemotherapy.
PC3 -Varying voltage and Bleomycin
In-vivo treatment of the tumours was performed in nude mice with the flexible electrodes attached to a biopsy jaw in order to demonstrate its suitability for future clinical use. Full regression of OE19 tumour xenographs was observed in four out of six electrochemotherapy treated oesophageal The remaining two nodules were subsequently eliminated by repeating the procedure after three weeks (figure 4). Similar results were obtained for the prostate, renal, and colon tumours. The fibrosarcoma and breast cell lines had very aggressive growth rates which were stabilised following electrochemotherapy. Although the tumours were not eliminated their growth rates did not change in the three weeks after therapy. Tumour growth rates were only affected in all cases in those treated with electrochemotherapy. 
IV. DISCUSSION
The flexible electrodes discussed in this paper provide a means to expand the use of electrochemotherapy to solid mass tumours normally considered inaccessible to conventional surgical therapies. We have shown the flexible design of the electrode allows for its deployment to the shape or contour of the tumour and is stable at the voltages used for multiple treatments. In these experiments the electrodes are applied to the skin surface and thus the electrical field crosses two layers of skin and the underlying tumour tissue. Therapeutic cell injury is confined to the zone of bleomycin delivery by direct injection of the drug into the tumour. This system may therefore be modified for human use in the application of electrochemotherapy to cutaneous or surface tumours such as breast, malignant melanoma, skin cancer, cutaneous metastases and some sarcoma's. The restrictions on the technique itself are limited to the electric field generated as opposed to the chemosensitivity of the tumours, as exposure to the electric field universally increases the uptake by cells of bleomycin several hundred fold. We and others have experience in the treatment of cutaneous tumours in humans with electrochemotherapy using needle electrode. The side effects compared with normal bleomycin chemotherapeutic doses are negligible because of its inability to enter non-permeabilised cells, and it is eliminated predominately by renal excretion within four hours. The total procedure itself is completed in a matter of minutes and is quite amenable to endoscopic delivery, with the electric pulses delivered in a few milliseconds.
Luminal tumours such as those of the foregut, colon and bladder, usually involve ulceration of the surface epithelium and thus the electrodes may be applied onto the cancer. In this paper we suggest that mounting flexible electrodes on an endoscopic biopsy or pincer system may facilitate endoscopically delivered electrochemotherapy or electrogenetherapy to such tumours.
V. CONCLUSION
Flexible electrodes may be fabricated for electroporation enhanced delivery of genes and drugs to cells and tissues. Successful deployment of these electrodes in endoscopic biopsy forceps, suggest that they may be used in minimally invasive surgical or endoscopic therapy systems. Most solid tumours are responsive to electrochemotherapy.
